Why did earlier myostatin drugs fail?

Several raised muscle size modestly but did not improve strength or function enough in muscle-disease trials.

What does myostatin do?

It limits muscle growth; blocking it increases muscle mass in animals.

Is there an approved myostatin inhibitor?

Yes. Apitegromab (Isembyld) was FDA approved in September 2026 for spinal muscular atrophy in people already on SMN2-targeted treatment.

Do myostatin inhibitor supplements work?

There is no good human evidence that supplements or research peptides sold as myostatin inhibitors build muscle.

Myostatin: The Muscle Brake and the Drugs That Block It

Myostatin explained: the protein that limits muscle growth, inhibitors like follistatin, bimagrumab and newly approved apitegromab, and the evidence. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Myostatin (GDF-8) is a protein made by muscle that limits how large muscles grow. Animals and rare people born without working myostatin have unusually high muscle mass, which made it a drug target for muscle-wasting diseases. In September 2026 the FDA approved apitegromab (Isembyld), an antibody that blocks myostatin activation, for spinal muscular atrophy alongside existing SMN2 treatments; its label warns of fractures. Bimagrumab, which blocks the receptor myostatin uses, is in trials with GLP-1 drugs to preserve muscle during weight loss (Bimagrumab).

Supplements and research peptides

Products marketed as myostatin inhibitors, from follistatin 344 injections to supplements, have no controlled human evidence of building muscle in healthy people. Several earlier myostatin drugs failed or were stopped in trials. WADA bans myostatin inhibitors in sport. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance. Last reviewed: October 2026.

Myostatin-targeting drugs at a glance

Last reviewed October 15, 2026.

Drug	How it works	Status
Apitegromab (Isembyld)	Antibody blocking myostatin activation	FDA approved September 2026 for spinal muscular atrophy
Bimagrumab	Blocks activin type II receptors	Trials with GLP-1 drugs for muscle-preserving weight loss
Domagrozumab, landogrozumab and others	Myostatin antibodies	Stopped after failing to improve function in muscle diseases
Follistatin	Natural binder of myostatin	Gene-therapy research only; injectable research products unproven

More confessions from the archive

Community Q&A

Why did earlier myostatin drugs fail?: Several raised muscle size modestly but did not improve strength or function enough in muscle-disease trials.
What does myostatin do?: It limits muscle growth; blocking it increases muscle mass in animals.
Is there an approved myostatin inhibitor?: Yes. Apitegromab (Isembyld) was FDA approved in September 2026 for spinal muscular atrophy in people already on SMN2-targeted treatment.
Do myostatin inhibitor supplements work?: There is no good human evidence that supplements or research peptides sold as myostatin inhibitors build muscle.
Are myostatin inhibitors banned in sport?: Yes, WADA prohibits them.

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.